Abstract
FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7+9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections.
Competing Interest Statement
This research was funded by Tutela Pharmaceuticals Inc., a 501(c)(3) not-for-profit pharmaceutical company. William E. Fitzsimmons is the Founder and Chair of Tutela Pharmaceuticals Inc. This work was supported by the Intramural Research Program of National Center for Advancing Translational Sciences, Sciences, National Institutes of Health
Footnotes
Appendix file added